Trial Profile
A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms DEPICT-5
- Sponsors AstraZeneca
- 27 Mar 2019 According to an AstraZeneca media release, based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001), the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
- 26 Jun 2018 Results from 2 studies NCT01498185 and NCT02582814 presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.